Breaking News Instant updates and real-time market news.

IBB

iShares Nasdaq Biotechnology Index

$116.95

-0.11 (-0.09%)

06:26
08/07/18
08/07
06:26
08/07/18
06:26

iShares Nasdaq Biotechnology Index: Pivot points

The following are the pivot points for the iShares Nasdaq Biotechnology Index (IBB). Pivot High: $117.215, Pivot Low: $116.055. These were calculated using the DeMark method. It is generally believed to be bullish when price breaks out above the pivot high or bearish when price breaks down below the pivot low.

IBB iShares Nasdaq Biotechnology Index
$116.95

-0.11 (-0.09%)

11/14/17
CANT
11/14/17
NO CHANGE
Target $31
CANT
Overweight
Cantor sees TherapeuticsMD being added to Biotechnology Index on Dec. 15
Cantor Fitzgerald's Tracker Quants team predicts TherapeuticsMD (TXMD) will be added to the Nasdaq Biotechnology Index (IBB) on December 15 and that passive trackers will need to buy 34.5M shares of the company. This may provide additional share upside in the short term, Cantor analyst William Tanner tells investors in a research note. He reiterates an Overweight rating on TherapeuticsMD while trimming his price target for the shares to $31 from $32. The women's healthcare company closed yesterday up 23c to $5.90. Tanner continues to believe TherapeuticsMD's TX-004 will be an important new therapy for vulvar vaginal atrophy.
04/02/18
JEFF
04/02/18
NO CHANGE
JEFF
Buy
Alnylam weakness on Pfizer data a buying opportunity, says Jefferies
Jefferies analyst Maury Raycroft noted that Alnylam (ALNY) fell by over 8% on Thursday after Pfizer (PFE) announced that the phase 3 ATTR-ACT trial assessing tafamidis in TTR-CM met its primary endpoint and that Alnylam shares are trailing the iShares Nasdaq Biotechnology Index (IBB) again today. While he thinks the tafamidis data provide important clinical outcome results that support the need for treatment and benefit in TTR-CM, he also continues to believe the benefits of knocking down/depleting TTR in earlier-stage patients, as Alnylam's patisiran is meant to do, will lead to better objective improvements, Raycroft tells investors. The analyst, who recommends investors buy Alnylam amid the weakness, keeps a Buy rating on the stock.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.